Sclerotherapy-associated esophageal ulcers: lessons from a double-blind, randomized comparison of sucralfate suspension versus placebo
| Autor: | David Y. Graham, J. Lacey Smith, Neshan Tabibian |
|---|---|
| Rok vydání: | 1989 |
| Předmět: |
medicine.medical_specialty
Sucralfate medicine.medical_treatment Esophageal Diseases Esophageal and Gastric Varices Placebo Gastroenterology law.invention Random Allocation Double-Blind Method Suspensions Randomized controlled trial law Multicenter trial Internal medicine Sclerotherapy medicine Humans Radiology Nuclear Medicine and imaging Ulcer Clinical Trials as Topic Wound Healing business.industry Esophageal disease Sclerosing Solutions medicine.disease digestive system diseases Esophageal Ulcer Surgery Gastrointestinal Hemorrhage business medicine.drug |
| Zdroj: | Gastrointestinal Endoscopy. 35:312-315 |
| ISSN: | 0016-5107 |
| DOI: | 10.1016/s0016-5107(89)72799-1 |
| Popis: | We undertook a double-blind randomized trial to assess whether sucralfate suspension would accelerate healing of sclerotherapy-associated esophageal ulcers. Consecutive patients who underwent sclerotherapy were evaluated. Patients were prospectively endoscoped 4 days (range, 3 to 5 days) after sclerotherapy. Those with ulcers greater than 5 mm in diameter were randomized to receive sucralfate suspension, 4 g/day (10 ml four times a day), or placebo. Endoscopic evaluations were done weekly for the 4 weeks of therapy. Nineteen patients survived long enough to be evaluated; complete ulcer healing was scored as success. Nine patients (13 ulcers) received sucralfate and 10 patients (17 ulcers) received placebo. At the end of 4 weeks, 78% of ulcers in sucralfate-treated patients had healed compared with 40% in the placebo group (p = not significant). Large ulcers were found to heal more slowly (p = 0.03, life table analysis) and small ulcers were disproportionally represented in patients receiving sucralfate (67% compared with 40% in the placebo group). When ulcer size was taken into account, the possible drug advantage disappeared; ulcer size appears to be a major determinant of rate of healing of sclerotherapy-associated esophageal ulcers. A large multicenter trial will be required to identify whether sucralfate accelerates postsclerotherapy esophageal ulcer healing. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|